Most promising PTSD treatment may use ‘ecstasy’ or ‘magic mushrooms’ alongside psychotherapy

 

Post-COVID trauma and the war in Ukraine means that millions of people are suffering or are at an increased risk of developing an ‘epidemic’ of post-traumatic stress (PTSD). Now a new review suggests that combining established psychotherapy methods with newer pharmaceuticals may offer the best therapeutic approach to deal with the large-scale problems faced by the healthcare systems in different countries in coping with mass trauma. Psychedelic medications including MDMA (‘ecstasy’) and psilocybin (‘magic mushrooms’) show the greatest promise. This work is published in the August edition of the peer-reviewed journal European Neuropsychopharmacology. The study is the first to review the use of novel treatments alongside already accepted psychotherapy and psychological counselling. It shows that combining these therapies seem to offer the best hope for treatment, particularly in cases of mass trauma where there are limited resources, such as we are seeing at present. The most prominent effect of trauma is PTSD, which is a persistent and severely distressing neuropsychological condition triggered by witnessing or experiencing a traumatic event. Symptoms include intrusive memories, recurrent nightmares, avoidance, mood swings, and changes in physical and emotional reactions. Lead author Dr. Xenia Gonda (Semmelweis University, Budapest, Hungary) said: “Psychotherapy is still the first choice for PTSD treatment. There is no effective established pharmacological treatment specifically for PTSD. However, psychotherapies may have a limited availability, are very lengthy and expensive. In addition, there are several different psychotherapeutic methods and only very few evidence-based interventions. We are beginning to see new approaches to PTSD treatment, which combines psychotherapy and medication. Both the psychotherapy and the drug treatment have an effect independently, but they often work together synergistically.  There are several such drugs in development, but our review shows that newer psychedelic drugs seem to be the stand-out candidates in this treatment. It’s important to say that it’s not the psychedelic nature of the drugs that seem to have the beneficial effect in PTSD, these drugs seem to work, at least in part, by enhancing the actions of psychotherapy at a neurological level”. There are several treatments in development for use alongside psychotherapy in treating PTSD. The most promising drugs are psychedelics, such as MDMA (3,4-methylenedioxy-methamphetamine, commonly known as ‘ecstasy’, and psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine, commonly known as ‘magic mushroom’). The review found that MDMA-assisted psychotherapy showed the greatest promise so far, with 4 trials showing significantly superior outcomes to those experience by patients receiving only psychotherapy. Trials on the use of psilocybin, found naturally in certain mushrooms, also show promise, though additional data are still needed to validate the therapeutic benefits of psilocybin in the treatment of PTSD”. Commenting, Dr Santiago Madero (Hospital Clinic, Barcelona) said: “This review article comes at a moment where President Biden’s administration has said they anticipate regulators approving MDMA within the next two years for designated breakthrough therapies for PTSD, surely to be followed by the European regulatory agencies. If this is so, as the author states: “MDMA may revolutionize the treatment of PTSD and may provide much needed novel pharmacotherapy that provide therapeutic benefits beyond all current and existing pharmacotherapies”. This is an independent comment, Dr Madero was not involved in this work. The paper Invisible wounds: Suturing the gap between the neurobiology, conventional and emerging therapies for posttraumatic stress disorder (authors Xenia Gonda, Peter Döme, Berta Erdelyi-Hamza, Sandor Krause and Livia Priyanka Elek from Semmelweis University in Budapest, Hungary;  Samata Sharma and Frank Tarazi from Harvard Medical School in Boston, USA), is published in European Neuropsychopharmacology. The paper can be seen at: https://www.sciencedirect.com/science/article/abs/pii/S0924977X22002103 European Neuropsychopharmacology is an official journal of the European College of Neuropsychopharmacology (ECNP).